{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:45:40Z","timestamp":1792698340908,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-94073-3","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T08:15:56Z","timestamp":1744877756000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Engineering IL-10 and rapamycin to bind collagen leads to improved anti fibrotic efficacy in lung and kidney fibrosis"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9615-2249","authenticated-orcid":false,"given":"Michael J. V.","family":"White","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8400-2051","authenticated-orcid":false,"given":"Michal M.","family":"Raczy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8510-0497","authenticated-orcid":false,"given":"Erica","family":"Budina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Yuba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7190-7852","authenticated-orcid":false,"given":"Ani","family":"Solanki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ha-Na","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6469-5778","authenticated-orcid":false,"given":"Zheng Jenny","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura T.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijie","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron T.","family":"Alpar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0276-5456","authenticated-orcid":false,"given":"Jeffrey A.","family":"Hubbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"issue":"2","key":"94073_CR1","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/path.2277","volume":"214","author":"TA Wynn","year":"2008","unstructured":"Wynn, T. A. Cellular and molecular mechanisms of fibrosis. J. Pathol. 214 (2), 199\u2013210 (2008).","journal-title":"J. Pathol."},{"issue":"8","key":"94073_CR2","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nri1412","volume":"4","author":"TA Wynn","year":"2004","unstructured":"Wynn, T. A. Fibrotic disease and the T(H)1\/T(H)2 paradigm. Nat. Rev. Immunol. 4 (8), 583\u2013594 (2004).","journal-title":"Nat. Rev. Immunol."},{"key":"94073_CR3","doi-asserted-by":"crossref","unstructured":"Spagnolo, P. Novel treatments for idiopathic pulmonary fibrosis. Am. J. Med.  128 (5), 447 - 449 (2015).","DOI":"10.1016\/j.amjmed.2015.01.003"},{"issue":"2","key":"94073_CR4","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1517\/14656566.2014.867328","volume":"15","author":"A Xaubet","year":"2014","unstructured":"Xaubet, A., Serrano-Mollar, A. & Ancochea, J. Pirfenidone for the treatment of idiopathic pulmonary fibrosis. Expert Opin. Pharmacother. 15 (2), 275\u2013281 (2014).","journal-title":"Expert Opin. Pharmacother"},{"issue":"1","key":"94073_CR5","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1165\/rcmb.2016-0217OC","volume":"57","author":"L Knuppel","year":"2017","unstructured":"Knuppel, L. et al. A novel antifibrotic mechanism of nintedanib and Pirfenidone. Inhibition of collagen fibril assembly. Am. J. Respir Cell. Mol. Biol. 57 (1), 77\u201390 (2017).","journal-title":"Am. J. Respir Cell. Mol. Biol."},{"issue":"Suppl 1","key":"94073_CR6","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1186\/1755-1536-5-S1-S14","volume":"5","author":"TD Hewitson","year":"2012","unstructured":"Hewitson, T. D. Fibrosis in the kidney: is a problem shared a problem halved? Fibrogenesis Tissue Repair. 5 (Suppl 1), S14 (2012).","journal-title":"Fibrogenesis Tissue Repair."},{"key":"94073_CR7","unstructured":"OPTN. The Organ Procurement and Transplantation Network. Web-based statistical inquiry [online]. Accessed 2016 Aug 6 (2016)."},{"issue":"2","key":"94073_CR8","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1524-475X.2009.00466.x","volume":"17","author":"GS Schultz","year":"2009","unstructured":"Schultz, G. S. & Wysocki, A. Interactions between extracellular matrix and growth factors in wound healing. Wound Repair. Regen. 17 (2), 153\u2013162 (2009).","journal-title":"Wound Repair. Regen"},{"issue":"Pt 24","key":"94073_CR9","doi-asserted-by":"publisher","first-page":"4195","DOI":"10.1242\/jcs.023820","volume":"123","author":"C Frantz","year":"2010","unstructured":"Frantz, C., Stewart, K. M. & Weaver, V. M. The extracellular matrix at a glance. J. Cell. Sci. 123 (Pt 24), 4195\u20134200 (2010).","journal-title":"J. Cell. Sci."},{"key":"94073_CR10","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1146\/annurev-med-050214-013407","volume":"67","author":"A Zuk","year":"2016","unstructured":"Zuk, A. & Bonventre, J. V. Acute kidney injury. Annu. Rev. Med. 67, 293\u2013307 (2016).","journal-title":"Annu. Rev. Med."},{"key":"94073_CR11","doi-asserted-by":"crossref","unstructured":"Probst, C. K. et al. Vascular permeability in the fibrotic lung. Eur. Respir J. 56(1), p.1900100 (2020).","DOI":"10.1183\/13993003.00100-2019"},{"issue":"1","key":"94073_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nm1685","volume":"14","author":"AM Tager","year":"2008","unstructured":"Tager, A. M. et al. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat. Med. 14 (1), 45\u201354 (2008).","journal-title":"Nat. Med."},{"issue":"3","key":"94073_CR13","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1159\/000514314","volume":"145","author":"A Cai","year":"2021","unstructured":"Cai, A., Chatziantoniou, C. & Calmont, A. Vascular permeability: regulation pathways and role in kidney diseases. Nephron 145 (3), 297\u2013310 (2021).","journal-title":"Nephron"},{"issue":"3","key":"94073_CR14","doi-asserted-by":"publisher","first-page":"C712","DOI":"10.1152\/ajpcell.00526.2023","volume":"326","author":"MS Goligorsky","year":"2024","unstructured":"Goligorsky, M. S. Permissive role of vascular endothelium in fibrosis: focus on the kidney. Am. J. Physiol. Cell. Physiol. 326 (3), C712\u2013C723 (2024).","journal-title":"Am. J. Physiol. Cell. Physiol."},{"issue":"4","key":"94073_CR15","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/ki.1985.173","volume":"28","author":"SJ Bander","year":"1985","unstructured":"Bander, S. J. et al. Long-term effects of 24-hr unilateral ureteral obstruction on renal function in the rat. Kidney Int. 28 (4), 614\u2013620 (1985).","journal-title":"Kidney Int."},{"issue":"11","key":"94073_CR16","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/ki.2009.86","volume":"75","author":"RL Chevalier","year":"2009","unstructured":"Chevalier, R. L., Forbes, M. S. & Thornhill, B. A. Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int. 75 (11), 1145\u20131152 (2009).","journal-title":"Kidney Int."},{"issue":"4","key":"94073_CR17","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s11255-013-0520-1","volume":"46","author":"AC Ucero","year":"2014","unstructured":"Ucero, A. C. et al. Unilateral ureteral obstruction: beyond obstruction. Int. Urol. Nephrol. 46 (4), 765\u2013776 (2014).","journal-title":"Int. Urol. Nephrol."},{"key":"94073_CR18","doi-asserted-by":"crossref","unstructured":"Walters, D. M. & Kleeberger, S. R. Mouse models of bleomycin-induced pulmonary fibrosis. Curr Protoc Pharmacol, Chapter 5: p. Unit 5 46. (2008).","DOI":"10.1002\/0471141755.ph0546s40"},{"key":"94073_CR19","doi-asserted-by":"crossref","unstructured":"Oxburgh, L., et al., (Re)Building a Kidney. J Am Soc Nephrol, 2017. 28(5): p. 1370-1378.","DOI":"10.1681\/ASN.2016101077"},{"issue":"1","key":"94073_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1177\/0023677220909401","volume":"55","author":"J Atkinson","year":"2021","unstructured":"Atkinson, J. et al. Refining the unilateral ureteral obstruction mouse model: no Sham, no shame. Lab. Anim. 55 (1), 21\u201329 (2021).","journal-title":"Lab. Anim."},{"issue":"1","key":"94073_CR21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12890-023-02349-z","volume":"23","author":"A Gul","year":"2023","unstructured":"Gul, A. et al. Pulmonary fibrosis model of mice induced by different administration methods of bleomycin. BMC Pulm Med. 23 (1), 91 (2023).","journal-title":"BMC Pulm Med."},{"issue":"1","key":"94073_CR22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1615\/CritRevImmunol.v32.i1.30","volume":"32","author":"SS Iyer","year":"2012","unstructured":"Iyer, S. S. & Cheng, G. Role of Interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Crit. Rev. Immunol. 32 (1), 23\u201363 (2012).","journal-title":"Crit. Rev. Immunol."},{"issue":"11","key":"94073_CR23","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1023\/B:PHAM.0000048199.94510.b0","volume":"21","author":"H Rachmawati","year":"2004","unstructured":"Rachmawati, H. et al. Pharmacokinetic and biodistribution profile of Recombinant human interleukin-10 following intravenous administration in rats with extensive liver fibrosis. Pharm. Res. 21 (11), 2072\u20132078 (2004).","journal-title":"Pharm. Res."},{"issue":"4","key":"94073_CR24","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1089\/wound.2019.1032","volume":"9","author":"EH Steen","year":"2020","unstructured":"Steen, E. H. et al. The role of the Anti-Inflammatory cytokine Interleukin-10 in tissue fibrosis. Adv. Wound Care (New Rochelle). 9 (4), 184\u2013198 (2020).","journal-title":"Adv. Wound Care (New Rochelle)"},{"issue":"10","key":"94073_CR25","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1136\/thx.2005.056317","volume":"61","author":"K Nakagome","year":"2006","unstructured":"Nakagome, K. et al. In vivo IL-10 gene delivery attenuates bleomycin induced pulmonary fibrosis by inhibiting the production and activation of TGF-beta in the lung. Thorax 61 (10), 886\u2013894 (2006).","journal-title":"Thorax"},{"key":"94073_CR26","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.biomaterials.2019.02.017","volume":"203","author":"EA Shamskhou","year":"2019","unstructured":"Shamskhou, E. A. et al. Hydrogel-based delivery of Il-10 improves treatment of bleomycin-induced lung fibrosis in mice. Biomaterials 203, 52\u201362 (2019).","journal-title":"Biomaterials"},{"key":"94073_CR27","doi-asserted-by":"crossref","unstructured":"Jung, K., et al., Interleukin-10 Protects against Ureteral Obstruction-Induced Kidney Fibrosis by Suppressing Endoplasmic Reticulum Stress and Apoptosis. Int J Mol Sci, 23(18), p.10702 2022.","DOI":"10.3390\/ijms231810702"},{"issue":"1","key":"94073_CR28","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1186\/s12890-024-03260-x","volume":"24","author":"Y Li","year":"2024","unstructured":"Li, Y. et al. IL-10 deficiency aggravates cell senescence and accelerates BLM-induced pulmonary fibrosis in aged mice via PTEN\/AKT\/ERK pathway. BMC Pulm Med. 24 (1), 443 (2024).","journal-title":"BMC Pulm Med."},{"issue":"4","key":"94073_CR29","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S0016-5085(00)70134-X","volume":"118","author":"DR Nelson","year":"2000","unstructured":"Nelson, D. R. et al. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology 118 (4), 655\u2013660 (2000).","journal-title":"Gastroenterology"},{"issue":"3","key":"94073_CR30","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.cmet.2014.01.001","volume":"19","author":"J Li","year":"2014","unstructured":"Li, J., Kim, S. G. & Blenis, J. Rapamycin: one drug, many effects. Cell. Metab. 19 (3), 373\u2013379 (2014).","journal-title":"Cell. Metab."},{"key":"94073_CR31","first-page":"2197","volume":"7","author":"HN Woo","year":"2012","unstructured":"Woo, H. N. et al. Preclinical evaluation of injectable sirolimus formulated with polymeric nanoparticle for cancer therapy. Int. J. Nanomed. 7, 2197\u20132208 (2012).","journal-title":"Int. J. Nanomed."},{"issue":"3","key":"94073_CR32","doi-asserted-by":"publisher","first-page":"e33626","DOI":"10.1371\/journal.pone.0033626","volume":"7","author":"G Chen","year":"2012","unstructured":"Chen, G. et al. Rapamycin ameliorates kidney fibrosis by inhibiting the activation of mTOR signaling in interstitial macrophages and myofibroblasts. PLoS One. 7 (3), e33626 (2012).","journal-title":"PLoS One"},{"issue":"5","key":"94073_CR33","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1165\/rcmb.2008-0377OC","volume":"41","author":"TR Korfhagen","year":"2009","unstructured":"Korfhagen, T. R. et al. Rapamycin prevents transforming growth factor-alpha-induced pulmonary fibrosis. Am. J. Respir Cell. Mol. Biol. 41 (5), 562\u2013572 (2009).","journal-title":"Am. J. Respir Cell. Mol. Biol."},{"issue":"11","key":"94073_CR34","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1038\/sj.ki.5000161","volume":"69","author":"MJ Wu","year":"2006","unstructured":"Wu, M. J. et al. Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis. Kidney Int. 69 (11), 2029\u20132036 (2006).","journal-title":"Kidney Int."},{"issue":"4","key":"94073_CR35","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.bbrc.2018.04.148","volume":"500","author":"Q Han","year":"2018","unstructured":"Han, Q. et al. Inhibition of mTOR ameliorates bleomycin-induced pulmonary fibrosis by regulating epithelial-mesenchymal transition. Biochem. Biophys. Res. Commun. 500 (4), 839\u2013845 (2018).","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6","key":"94073_CR36","doi-asserted-by":"publisher","first-page":"L887","DOI":"10.1152\/ajplung.00451.2020","volume":"319","author":"N Neumark","year":"2020","unstructured":"Neumark, N. et al. The idiopathic pulmonary fibrosis cell atlas. Am. J. Physiol. Lung Cell. Mol. Physiol. 319 (6), L887\u2013L893 (2020).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"94073_CR37","doi-asserted-by":"publisher","first-page":"2424751","DOI":"10.1155\/2019\/2424751","volume":"2019","author":"Y Cao","year":"2019","unstructured":"Cao, Y. et al. Decreased expression of urinary mammalian target of Rapamycin mRNA is related to chronic renal fibrosis in IgAN. Dis. Markers. 2019, 2424751 (2019).","journal-title":"Dis. Markers"},{"issue":"1","key":"94073_CR38","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12943-023-01820-z","volume":"22","author":"A Marques-Ramos","year":"2023","unstructured":"Marques-Ramos, A. & Cervantes, R. Expression of mTOR in normal and pathological conditions. Mol. Cancer. 22 (1), 112 (2023).","journal-title":"Mol. Cancer"},{"key":"94073_CR39","doi-asserted-by":"crossref","unstructured":"Ishihara, J. et al. Targeted antibody and cytokine cancer immunotherapies through collagen affinity. Sci. Transl Med. 11(487), p. eaau3259 (2019).","DOI":"10.1126\/scitranslmed.aau3259"},{"issue":"11","key":"94073_CR40","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1002\/ijc.23408","volume":"122","author":"A Villa","year":"2008","unstructured":"Villa, A. et al. A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int. J. Cancer. 122 (11), 2405\u20132413 (2008).","journal-title":"Int. J. Cancer"},{"issue":"22","key":"94073_CR41","doi-asserted-by":"publisher","first-page":"10948","DOI":"10.1158\/0008-5472.CAN-07-1436","volume":"67","author":"JN Rybak","year":"2007","unstructured":"Rybak, J. N. et al. The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases. Cancer Res. 67 (22), 10948\u201310957 (2007).","journal-title":"Cancer Res."},{"issue":"5","key":"94073_CR42","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41551-020-0549-2","volume":"4","author":"A Mansurov","year":"2020","unstructured":"Mansurov, A. et al. Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours. Nat. Biomed. Eng. 4 (5), 531\u2013543 (2020).","journal-title":"Nat. Biomed. Eng."},{"issue":"1","key":"94073_CR43","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12890-018-0626-4","volume":"18","author":"M Molina-Molina","year":"2018","unstructured":"Molina-Molina, M. et al. Anti-fibrotic effects of Pirfenidone and Rapamycin in primary IPF fibroblasts and human alveolar epithelial cells. BMC Pulm Med. 18 (1), 63 (2018).","journal-title":"BMC Pulm Med."},{"key":"94073_CR44","doi-asserted-by":"crossref","unstructured":"Plate, M., Guillotin, D. & Chambers, R. C. The promise of mTOR as a therapeutic target pathway in idiopathic pulmonary fibrosis. Eur. Respir Rev. 29(157), p. 200269 (2020).","DOI":"10.1183\/16000617.0269-2020"},{"issue":"48","key":"94073_CR45","doi-asserted-by":"publisher","first-page":"7859","DOI":"10.1039\/C6TB02364A","volume":"4","author":"H Wen","year":"2016","unstructured":"Wen, H. et al. Redox-mediated dissociation of PEG-polypeptide-based micelles for on-demand release of anticancer drugs. J. Mater. Chem. B. 4 (48), 7859\u20137869 (2016).","journal-title":"J. Mater. Chem. B"},{"issue":"11","key":"94073_CR46","doi-asserted-by":"publisher","first-page":"peaay1971","DOI":"10.1126\/sciadv.aay1971","volume":"5","author":"K Katsumata","year":"2019","unstructured":"Katsumata, K. et al. Targeting inflammatory sites through collagen affinity enhances the therapeutic efficacy of anti-inflammatory antibodies. Sci. Adv. 5 (11), peaay1971 (2019).","journal-title":"Sci. Adv."},{"key":"94073_CR47","doi-asserted-by":"crossref","unstructured":"White, M.J.V., et al., Blocking antibodies against integrin-\u03b13, -\u03b1M, and -\u03b1M\u03b22 de-differentiate myofibroblasts, and improve lung fibrosis and kidney fibrosis. Scientific Reports. 14(1), p. 21623 2024.","DOI":"10.1038\/s41598-024-70737-4"},{"issue":"2","key":"94073_CR48","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3109\/10837450.2012.757782","volume":"19","author":"Y Wei","year":"2014","unstructured":"Wei, Y. & Zhao, L. Passive lung-targeted drug delivery systems via intravenous administration. Pharm. Dev. Technol. 19 (2), 129\u2013136 (2014).","journal-title":"Pharm. Dev. Technol."},{"key":"94073_CR49","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3389\/fmolb.2020.00193","volume":"7","author":"Y Yao","year":"2020","unstructured":"Yao, Y. et al. Nanoparticle-Based drug delivery in cancer therapy and its role in overcoming drug resistance. Front. Mol. Biosci. 7, 193 (2020).","journal-title":"Front. Mol. Biosci."},{"issue":"5","key":"94073_CR50","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1002\/art.41585","volume":"73","author":"E Yuba","year":"2021","unstructured":"Yuba, E. et al. Suppression of rheumatoid arthritis by enhanced lymph node trafficking of engineered Interleukin-10 in murine models. Arthritis Rheumatol. 73 (5), 769\u2013778 (2021).","journal-title":"Arthritis Rheumatol."},{"issue":"5","key":"94073_CR51","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41551-020-00627-3","volume":"5","author":"A Ishihara","year":"2021","unstructured":"Ishihara, A. et al. Prolonged residence of an albumin-IL-4 fusion protein in secondary lymphoid organs ameliorates experimental autoimmune encephalomyelitis. Nat. Biomed. Eng. 5 (5), 387\u2013398 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"94073_CR52","doi-asserted-by":"crossref","unstructured":"Michael, J. V. et al. Myofibroblast differentiation is governed by adhesion mechanics, and inhibition of the stress sensor Talin2 reverses lung fibrosis. 2021.  bioRxiv, DOI: https:\/\/doi.org\/10.1101\/2021.06.07.447403.","DOI":"10.1101\/2021.06.07.447403"},{"issue":"1","key":"94073_CR53","doi-asserted-by":"publisher","first-page":"31","DOI":"10.4103\/2229-516X.149232","volume":"5","author":"L Ray","year":"2015","unstructured":"Ray, L. et al. A comparative study of serum aminotransferases in chronic kidney disease with and without end-stage renal disease: need for new reference ranges. Int. J. Appl. Basic. Med. Res. 5 (1), 31\u201335 (2015).","journal-title":"Int. J. Appl. Basic. Med. Res."},{"issue":"8","key":"94073_CR54","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1002\/art.27498","volume":"62","author":"A Yoshizaki","year":"2010","unstructured":"Yoshizaki, A. et al. Treatment with Rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis. Arthritis Rheum. 62 (8), 2476\u20132487 (2010).","journal-title":"Arthritis Rheum."},{"issue":"3","key":"94073_CR55","doi-asserted-by":"publisher","first-page":"192092","DOI":"10.1098\/rsos.192092","volume":"7","author":"H Li","year":"2020","unstructured":"Li, H. et al. Influence factors on the critical micelle concentration determination using pyrene as a probe and a simple method of Preparing samples. R Soc. Open. Sci. 7 (3), 192092 (2020).","journal-title":"R Soc. Open. Sci."},{"issue":"4","key":"94073_CR56","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1039\/C3NR05961H","volume":"6","author":"M Sethi","year":"2014","unstructured":"Sethi, M. et al. Effect of drug release kinetics on nanoparticle therapeutic efficacy and toxicity. Nanoscale 6 (4), 2321\u20132327 (2014).","journal-title":"Nanoscale"},{"issue":"2","key":"94073_CR57","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1124\/jpet.105.095042","volume":"316","author":"I Bergheim","year":"2006","unstructured":"Bergheim, I. et al. Critical role of plasminogen activator inhibitor-1 in cholestatic liver injury and fibrosis. J. Pharmacol. Exp. Ther. 316 (2), 592\u2013600 (2006).","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94073-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94073-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94073-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T10:02:24Z","timestamp":1744884144000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94073-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["94073"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-94073-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,17]]},"assertion":[{"value":"18 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JAH is founder and shareholder of HeioThera, Inc, which has licensed the variants of IL-10 described herein from the University of Chicago. The other authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All the animal experiments performed in this work were approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Chicago, and was reported in this manuscript using ARRIVE guidelines. All mouse experiments were performed under supervision with protocols approved by the University of Chicago IACUC, and the study was performed in accordance with the relevant guidelines and regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"13279"}}